Phase 3Completed
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia (BERSON)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia (BERSON)
- Sponsor
- Amgen (Industry)
- Enrollment
- 986 enrolled
- Conditions
- Diabetes, Hyperlipidemia, Mixed Dyslipidemia
- Interventions
- Evolocumab; Atorvastatin; Placebo
- Ages
- adults, older adults
- Registry
- NCT02662569, EUCTR2013-000723-14
Full record on ClinicalTrials.gov
From the registry
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in diabetic adults with hyperlipidemia or mixed dyslipidemia.
Primary outcomes
- Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
- Percent Change From Baseline in LDL-C at Week 12
History
Results first posted
Last registry update
Primary completion
Started
Registered